Literature DB >> 14758817

Uptake of BRCA1 genetic testing in adult sisters and daughters of known mutation carriers in Norway.

Trine Levin Bodd1, Jon Reichelt, Ketil Heimdal, Pal Moller.   

Abstract

This study was undertaken to examine transmission of information to first-degree relatives of BRCA1 mutation carriers and uptake of genetic testing. The intention was to consider revision of current legislation related to privacy if information on life-saving health care was not disseminated to at-risk family members. The Norwegian Radium Hospital provides clinical genetics services for families at high risk for hereditary breast and ovarian cancer. Together with major hospitals nationwide we provide medical surveillance. Nearly all expenses are covered by the National Health insurance. Because of the high number of families with founder mutations in BRCA1, we are in a unique position to gather information about these groups. Within a consecutive series, we identified 75 BRCA1 mutation carriers and registered information transmission and uptake of genetic testing 6 months or more after the index mutation carriers had been informed about their mutation status. These 75 BRCA1 mutation carriers had 172 living first-degree relatives, aged 18 years or older (84 females, 88 males). Forty-four out of 54 (81.5%) of females over 30 had opted for genetic testing. The testing rate among all relatives was 43%. At any age, 63 % of the females underwent genetic testing compared with 24% of the males (p<0.05%). The overwhelming majority of adult females at risk opted for genetic testing. Males with daughters more frequently than males without daughters asked for testing. The findings give neither reason to reconsider legislation on privacy, nor for us to consider more aggressive methods of contacting relatives.

Entities:  

Keywords:  Empirical Approach; Genetics and Reproduction

Mesh:

Year:  2003        PMID: 14758817     DOI: 10.1023/a:1025864703405

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  22 in total

1.  Psychosocial factors predicting BRCA1/BRCA2 testing decisions in members of hereditary breast and ovarian cancer families.

Authors:  B B Biesecker; N Ishibe; D W Hadley; T R Giambarresi; R G Kase; C Lerman; J P Struewing
Journal:  Am J Med Genet       Date:  2000-08-14

2.  Predictive genetic testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction.

Authors:  K Aktan-Collan; J P Mecklin; H Järvinen; M Nyström-Lahti; P Peltomäki; I Söderling; A Uutela; A de la Chapelle; H Kääriäinen
Journal:  Int J Cancer       Date:  2000-01-20       Impact factor: 7.396

3.  Uptake of genetic testing and pre-test levels of mental distress in Norwegian families with known BRCA1 mutations.

Authors:  J G Reichelt; A A Dahl; K Heimdal; P Møller
Journal:  Dis Markers       Date:  1999-10       Impact factor: 3.434

4.  [Information to families with hereditary breast and ovarian cancer].

Authors:  T Levin; J Reichelt; K Heimdal; P Møller
Journal:  Tidsskr Nor Laegeforen       Date:  2001-11-20

5.  Identification of the breast cancer susceptibility gene BRCA2.

Authors:  R Wooster; G Bignell; J Lancaster; S Swift; S Seal; J Mangion; N Collins; S Gregory; C Gumbs; G Micklem
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

6.  Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families. The French Cancer Genetic Network.

Authors:  C Julian-Reynier; H Sobol; C Sévilla; C Noguès; P Bourret
Journal:  Psychooncology       Date:  2000 Nov-Dec       Impact factor: 3.894

7.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Authors:  Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

8.  Attitudes about genetic testing for breast-ovarian cancer susceptibility.

Authors:  C Lerman; M Daly; A Masny; A Balshem
Journal:  J Clin Oncol       Date:  1994-04       Impact factor: 44.544

9.  The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer.

Authors:  K Heimdal; L Maehle; J Apold; J C Pedersen; P Møller
Journal:  Eur J Cancer       Date:  2003-10       Impact factor: 9.162

10.  Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort.

Authors:  C Foster; D G R Evans; R Eeles; D Eccles; S Ashley; L Brooks; R Davidson; J Mackay; P J Morrison; M Watson
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

View more
  14 in total

1.  Letting the family know: balancing ethics and effectiveness when notifying relatives about genetic testing for a familial disorder.

Authors:  G K Suthers; J Armstrong; J McCormack; D Trott
Journal:  J Med Genet       Date:  2005-12-21       Impact factor: 6.318

2.  The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.

Authors:  Fred H Menko; Jacqueline A Ter Stege; Lizet E van der Kolk; Kiki N Jeanson; Winnie Schats; Daoud Ait Moha; Eveline M A Bleiker
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

Review 3.  Men's decision-making about predictive BRCA1/2 testing: the role of family.

Authors:  N Hallowell; A Ardern-Jones; R Eeles; C Foster; A Lucassen; C Moynihan; M Watson
Journal:  J Genet Couns       Date:  2005-06       Impact factor: 2.537

4.  Psychological distress in women at risk of hereditary breast/ovarian or HNPCC cancers in the absence of demonstrated mutations.

Authors:  Amy Østertun Geirdal; Jon G Reichelt; Alv A Dahl; Ketil Heimdal; Lovise Maehle; Astrid Stormorken; Pål Møller
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

5.  High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series.

Authors:  Pål Møller; Lovise Mæhle; Lars F Engebretsen; Trond Ludvigsen; Christoffer Jonsrud; Jaran Apold; Anita Vabø; Neal Clark
Journal:  Hered Cancer Clin Pract       Date:  2010-01-19       Impact factor: 2.857

6.  Towards evidence-based management of inherited breast and breast-ovarian cancer.

Authors:  Pål Møller
Journal:  Hered Cancer Clin Pract       Date:  2004-12-15       Impact factor: 2.857

7.  The relationship between psychological distress and personality in women from families with familial breast/ovarian or hereditary non-polyposis colorectal cancer in the absence of demonstrated mutations.

Authors:  Amy Østertun Geirdal; Alv A Dahl
Journal:  J Genet Couns       Date:  2008-07-08       Impact factor: 2.537

8.  Uptake of predictive testing among relatives of BRCA1 and BRCA2 families: a multicenter study in northeastern Spain.

Authors:  Judit Sanz; Teresa Ramón y Cajal; Asunción Torres; Esther Darder; Neus Gadea; Angela Velasco; Daniel Fortuny; Consol López; David Fisas; Joan Brunet; M Carmen Alonso; Judith Balmaña
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

9.  Psychological and cancer-specific distress at 18 months post-testing in women with demonstrated BRCA1 mutations for hereditary breast/ovarian cancer.

Authors:  Jon G Reichelt; Pål Møller; Ketil Heimdal; Alv A Dahl
Journal:  Fam Cancer       Date:  2008-01-25       Impact factor: 2.375

10.  No sib pair concordance for breast or ovarian cancer in BRCA1 mutation carriers.

Authors:  Pål Møller; Lovise Maehle; Neal Clark; Jaran Apold
Journal:  Hered Cancer Clin Pract       Date:  2007-06-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.